Studies and sources

Staresinic and colleagues, 2003. Rat Achilles-tendon injury and tendon-cell work. The reported healing findings are preclinical; they do not establish a human recovery benefit or a dosing schedule.

Xue and colleagues, 2004. Gastric-ulcer experiments in rats. The study helps explain the compound’s early digestive focus, while its species and experimental injuries limit what can be concluded about human symptoms.

Hsieh and colleagues, 2017. Cultured vascular cells, a chick-membrane model and rats with restricted blood flow. The work examines a proposed receptor pathway; it is not a clinical recovery trial.

A 2025 report in Alternative Therapies in Health and Medicine. Two adults received intravenous BPC-157. The small sample and safety focus cannot establish efficacy, uncommon harms or the consequences of long-term exposure.

McGuire and colleagues, 2025. A narrative review of musculoskeletal evidence. It discusses broad preclinical findings and a very small published human record; a narrative synthesis is not a new controlled trial.

FDA, July 2026 advisory-committee material. An assessment of chemical identity, human and animal evidence, and safety concerns. It considers more study material than the published pilots alone and keeps regulatory evaluation separate from drug approval.

FDA, July 2026 advisory-committee material. The assessment distinguishes the capped fragment from full-length thymosin beta-4 and discusses the absence of published human TB-500 studies. It does not establish a clinical use for the fragment.

Irobi and colleagues, 2004. A structural experiment on the full protein’s interaction with actin. It explains a molecular relationship, not an outcome from treating an injury with TB-500.

Morris and colleagues, 2014. A rat stroke study of the full protein, with different outcomes at different tested amounts. These animal findings cannot supply a human regimen or a TB-500 efficacy result.

Ruff and colleagues, 2010. A placebo-controlled intravenous study in forty healthy volunteers. It addresses early tolerability and pharmacokinetics of the full protein, rather than healing efficacy or the fragment’s safety.

Goldstein and colleagues, 2012. A review of the parent protein’s experimental biology and clinical applications under investigation. Its scope includes mechanisms that cannot simply be assigned to the shorter fragment.

Mendias and Awan, 2026. A sports-medicine review considering approved and unapproved peptides. It places recovery claims beside the limitations of rigorous human evidence and the relevant safety and sporting concerns.

Pickart and colleagues, 2015. A review spanning laboratory work and reports of topical studies. Some human findings are summarized from sources that are not full journal trial reports; those limits remain relevant.

Mortazavi and colleagues, 2025. A review of topical GHK, formulation challenges and the clinical evidence gap. It helps explain why effects in cultured cells do not establish the performance of a skin preparation.

Lee and colleagues, 2016. Forty-five men were followed for six months with a topical combination and placebo. The peptide was free GHK, and the combined ingredients prevent attribution to GHK-Cu alone.

Hostynek and colleagues, 2011. An experiment using human skin outside the body. It measured copper delivery and retention, not the clinical effect of a topical preparation or the safety of injections.

FDA’s page, current as of April 22, 2026. It lists BPC-157, TB-500 and injectable GHK-Cu as nominated but withdrawn and retains safety concerns. Withdrawal does not mean clearance, drug approval or permission to compound.